New approaches to the treatment of depression

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 4, 1996, Pages 26-33

  Leonard, Brian E ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN 1A AGONIST;

DEPRESSION; DRUG MECHANISM; HUMAN; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; REVIEW; SEROTONIN RELEASE;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN; BUPROPION; CITALOPRAM; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DOPAMINE; HUMANS; RECEPTORS, DOPAMINE; RECEPTORS, GABA; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, SEROTONIN; SEROTONIN; THIOPHENES;

EID: 0029938302     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Leonard BE. Biochemical strategies for the development of antidepressanls. CNS Drugs 1994;1:285-304
2. Norman TR, Leonard BE. Fast acting antidepressants: can the need be met? CNS Drugs 1994;2:120-131
3. Leonard BE. Neurotransmitter receptors, endocrine responses and the biological substrates of depression: a review. Human Psychopharmacology 1986;1:3-18
4. Van Praag HM, Korf J, Puite J. 5-Hydroxyindole acetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid [letter]. Nature 1970;225:827
5. Åsberg M, Ruigberger A, Sjoqvist F, et al. Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with clomipramine. J Clin Pharm Ther 1977;21:2012-2017
6. Leonard BE. Effect of antidepressants on specific neurotransmitters: are such effects relevant to their therapeutic action? In: Den Boer JA, van Sitzen JAM, eds. Handbook of Depression and Anxiety: A Biological Approach. New York, NY: Marcel Dekker; 1994:379-404
7. Potter WZ, Grossman F, Rudorfer MV. Noradrenergic function in depressive disorders. In: Mann JJ, Kupfer DJ, eds. Biology of Depressive Disorders, Part A: A Systems Perspective. New York, NY: Plenum Press; 1993:1-28
8. Malone K, Mann JJ. Serotonin in major depression. In: Mann JJ, Kupfer DJ, eds. Biology of Depressive Disorders, Part A: A Systems Perspective. New York, NY: Plenum Press; 1993:29-50
9. Meyerson LR, Wennogle LP, Abel MS, et al. Human brain receptor alteration in suicide victims. Pharmacol Biochem Behav 1982;17:159-163
10. Stanley M, Mann JJ. Increased serotonin binding sites in frontal cortex of suicide victims. Lancet 1983;1:214-216
11. Risch SS, Kalin NH, Janowsky DS, et al. Response to central cholinergic stimulation. Science 1983;72:222
12. Janowsky DS, Risch SSC. Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorders in stress. Drug Development and Research 1984;4:125-142
13. Janowsky DS, Risch SSC, Gillin JC. Adrenergic-cholinergic balance and the treatment of affective disorders. Prog Neuropsychopharmacol Biol Psychiatry 1983;7:297-307
14. Charney DS, Suthwick SM, Delgado PL, et al. Current status of the receptor sensitivity hypothesis of antidepressant action. In: Amsterdam JD, ed. Pharmacotherapy of Depression. New York, NY: Marcel Dekker; 1990: 13-27
15. Leonard BE. Effects of antidepressants and neurotransmission: a common mechanism of action? In: Osborne NN, ed. Current Aspects of the Neuro-sciences, vol 4. Basingstoke, UK: Macmillan; 1992:205-238
16. Willner P. Depression: A Psychobiological Synthesis. New York, NY: Wiley Interscience; 1985
17. Leonard BE. Serotonin receptors: where are they going? Int Clin Psychopharmacol 1994;9(suppl 1):7-18
18. Peroutka SJ, Snyder SH. Long-term antidepressant treatment decreases spiroperidol-labelled serotonin receptor binding. Science 1980;210:88-90
19. 3H]-spiperone binding in rat frontal cortex and serotonin receptor mediated behaviour. Psychopharmacology 1983;80:150-155
20. Ogren SO, Fuxe K. Effects of antidepressant drugs on central serotonin receptors. In: Green AR, ed. Neuropharmacology of Serotonin. Oxford, England-Oxford University Press; 1985:131-180
21. Johnson AM. The comparative pharmacological properties of selective serotonin reuptake inhibitors in animals. In: Feighner J. Boyer WF, eds. Selective Serotonin Reuptake Inhibitors. Chichester, UK: John Wiley & Sons; 1991:37-70
22. de Montigny C, Chaput Y, Blier P. Modification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers. J Clin Psychiatry 1990;51(12, suppl B):4-8
23. 1A Receptors. Chichester, UK: Ellis Horwood; 1987:34-51
24. Goodwin GM, De Sura RJ, Green AR. Presynaptic serotonin receptor mediated response in mice attenuated by antidepressant drugs and electroconvulsive shock. Nature 1985;317:531-533
25. Aghajanian GK, de Montigny C. Tricyclic antidepressants: long-term treatment increases responsivity of rat forebrain neurons to serotonin. Science 1978;202:1303-1306
26. Blier P, de Montigny C, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatment: preclinical evidence. J Clin Psychiatry 1990;51(4, suppl): 14-20
27. Chaput Y, de Montigny C, Blier P. Effects of a selective 5-HT reuptake blocker citalopram on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat. Naunyn Schmiedebergs Arch Pharmacol 1986; 33:342-349
28. de Montigny C, Chaput YU, Blier P. Classical and novel targets of antidepressant drugs. In: Mendlewicz J, Brunello N. Langer SZ, et al, eds. New Pharmacological Approaches to the Therapy of Depressive Disorders. Basel, Switzerland: Karger; 1993:8-17
29. Nelson DR, Thomas DR, Johnson AM. Pharmacological effects of paroxetine after repeated administration to animals. Acta Psychiatr Scand Suppl 1989;80(suppl 350):21-23
30. 2 receptor transmembrane signalling system. Psychopharmacology 1992;99:64-69
31. Deakin JFDW, Guimarraes FS, Wang M, et al. Experimental tests of the 5-HT receptor imbalance theory of affective disorders. In: Sandler M, Coppen A, Harnett S, eds. 5-Hydroxytryptamine in Psychiatry. Oxford, England: Oxford Medical Publications; 1991:143-154
32. Healy D, Carney PA, O'Halloran A, et al. Peripheral adrenoceptors and serotonin receptors in depression. J Affect Disord 1985;17:285-292
33. Butler J, Leonard BE. The platelet serotonergic system in depression and following sertraline treatment. Int J Clin Psychopharmacol 1988;3:343-347
34. Leonard BE. Mechanisms of action of antidepressants. CNS Drugs 1995;4:1-12
35. Grahame-Smith DG. Serotonin in affective disorders. Int Clin Psychopharmacol 1992;6(suppl 4):249-257
36. Guelfi JD, White C, Hackett D, et al. Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia. J Clin Psychiatry 1995;56:450-458
37. Derivan AJ. Antidepressants: can we determine how quickly they work? issues from the literature. Psychopharmacol Bull 1995;31:23-28
38. Baron DBM, Ogden AM, Siegal BW, et al. Rapid down regulators of beta adrenoceptors by co-administrators of desipramine and fluoxetine. Eur J Pharmacol 1988;154:125-134
39. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-220
40. Artigas F, Ferez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 1994;51:248-251
41. Artigas F. Selective serotonin/noradrenaline reuptake inhibitors (SNRIs). CNS Drugs 1995;4:79-89
42. Leonard BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993;54(8, suppl):3-15
43. O'Connor WT, Leonard BE. Effect of chronic administration of the 6 aza analogue of mianserin (Org 3770) and its enantiomers on behaviour and changes in noradrenaline metabolism of olfactory bulbectomized rats in the "open field" apparatus. Neuropharmacology 1986;25:267-270
44. de Boer T, Nefkens F, Van Helvoirt A. The alpha-2 antagonist Org 3770 enhances serotonin transmission in vivo. Eur J Pharmacol 1994;253:R5-R6
45. Smith WT, Glaudin V, Pangides J, et al. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990;26:191-196
46. Zivkov M, De Jongh G. Org 3770 vs amitriptyline: a 6 week randomized double-blind multicentre trial in hospitalized patients. Human Psychopharmacology 1995;10:173-180
47. Paul IA, Nowak G, Layer RT, et al. Adaptation of the NMDA receptor complex in rat frontal cortex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994;269:95-102
48. Largent BL, Wikstorm H, Gundlach AL, et al. Structural determinants of sigma receptor affinity. Mol Pharmacol 1987;32:732-784
49. Trallas R, Skolnik P. Functional antagonists at the NMDA receptor complex exhibits antidepressant actions. Eur J Pharmacol 1990;185:1-10
50. Skolnick P, Miller R, Young A. et al. Chronic treatment with 1-amino-cyclopropanecarboxylic acid desensitizes behavioural responses to compound acting at the N-methyl-D-aspartate receptor complex. Psychopharmacology 1992;107:489-496
51. Maj J, Rogoz Z, Skuza G, et al. The effects of MK-801 and antidepressant drugs in the forced slimming test in rats. Eur J Neuropsychopharmacol 1992;2:37-41
52. Papp M, Moryl E. Similar effects of chronic treatment with imipramine and the NMDA antagonists CGP3784 and MK801 in a chronic mild stress model of depression in rats. Eur J Neuropsychopharmacol 1993;3:348-349
53. Paul IA, Trullas R, Skolnick P, et al. Down regulation of cortical beta adrenoceptors by chronic treatment with functional NMDA antagonists. Psychopharmacology 1992;106:285-287
54. Paul IA, Trullas R, Skolnick P, et al. Adaptation of the NMDA receptor complex in rat frontal cortex following chronic treatment with electroconvulsive shock or imipramine. Eur J Pharmacol 1993;247:305-312
55. Ithak Y, Kassin CO. Clorgyline displays a high affinity for sigma binding sites in C57 BL6 mouse brain. Eur J Pharmacol 1990;176:107-108
56. 3H] haloperidol binding in guinea pig membranes. Proc Natl Acad Sci U S A 1984;81(17):5618-5621
57. Roman FJ, Pascaud XP, Duffy O, et al. Neuropeptide Y and peptide YY interact with rat brain sigma and PCP binding sites. Eur J Pharmacol 1989;174:301-302
58. Higuchi H, Costa E, Yang H-Y. Neuropeptide Y inhibits the nicotine mediated release of catecholamines from bovine adrenal chromaffin cells. J Pharmacol Exp Ther 1988;244:468-474
59. Paul IA, Nowak G, Young A, et al. In vitro modulation of sigma I receptors in mouse forebrain by antidepressant drugs. Eur J Pharmacol (Mol Pharmacol Sect). In press
60. Leonard BE. Second generation antidepressants: chemical diversity but unity of action? In: Montgomery S, Com TH, eds. Psychopharmacology of Depression. Oxford, England: Oxford University Press; 1994:19-31
61. Wong KL, Bruck RC, Farabman IA. Amitriptyline mediated inhibition of neunte outgrowth from chick's embryonic cerebral explants involves a reduction in adenylate cyclase activity. J Neurochem 1991;57:1223-1230
62. Racagni G, Tinelli D, Bianchi E, et al. cAMP-dependent binding proteins and endogenous phosphorylation after antidepressant treatment. In: Sandler M, Coppen A, Hamett S, eds. 5-Hydroxytryptamine in Psychiatry. Oxford, England: Oxford Medical Publications; 1991:116-123
63. van Eekelen JAM, Kiss JZ, Westphal HM, et al. Immunocytochemical study on the intracellular localization of the type 2 glucocorticoid receptor in the rat brain. Brain Res 1987;436:120-128
64. Burnstein XL, Cidlowski JA. Regulation of gene expression by glucocorticoids. Ann Rev Physiol 1989;51:683-699
65. Kitayama I, Janson AM, Cintra A. Effects of chronic imipramine treatment on glucocorticoid receptor immunoreactivity in various regions of the rat brain. J Neural Transm 1988;73:191-203
66. Dinan TG. Glucocorticoids and the genesis of depressive illness: a psychobiological model. Br J Psychiatry 1994;164:365-371
67. Song C, Leonard BE. The effect of olfactory bulbectomy in the rat alone or in combination with antidepressants and endogenous factors, on immune function. Human Psychopharmacology 1995;10:7-18